Purple Biotech (PPBT) Share-based Compensation (2017 - 2026)
Purple Biotech's (PPBT) quarterly Share-based Compensation came in at $93000.0 in Q1 2026, little changed year-on-year from $93000.0 in Q1 2025, and up 316.28% on a QoQ basis from -$43000.0 in Q4 2025.
Purple Biotech (PPBT) Share-based Compensation (2017 - 2026) Analysis & Trends
Purple Biotech (PPBT) has 10 years of Share-based Compensation data on file, last reported at $93000.0 in Q1 2026.
- On a quarterly basis, Share-based Compensation changed 0.0% year-over-year to $93000.0 in Q1 2026; TTM through Mar 2026 was $309000.0, a 24.45% decrease from a year earlier, with the FY2025 full-year figure at $309000.0, down 46.91% from the prior year.
- Share-based Compensation for Q1 2026 stood at $93000.0, up from -$43000.0 in the prior quarter.
- Over the last five years, Share-based Compensation for PPBT reached as high as $839000.0 in Q4 2022 and fell as low as -$43000.0 in Q4 2025.
- Historically, Share-based Compensation has averaged $310058.8 across 5 years, with a median of $218000.0 in 2024.
- Across the five-year window, Share-based Compensation jumped 143.37% in 2023 and slumped 118.78% in 2024, its largest moves.
- Year by year, Share-based Compensation stood at $839000.0 in 2022, then slumped by 78.43% to $181000.0 in 2023, then sank by 118.78% to -$34000.0 in 2024, then dropped by 26.47% to -$43000.0 in 2025, then surged by 316.28% to $93000.0 in 2026.
- Per Business Quant data, the three most recent Share-based Compensation figures were $93000.0 in Q1 2026, -$43000.0 in Q4 2025, and $200000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 6.39 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 9.26 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 1.18 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 166.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 257.40 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 87.30 Mn |
| 10 | Purple Biotech | 1.33 Bn | 1.33 Bn | - | 93,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 93,000.00 |
| Mar 31, 2026 | 93,000.00 |
| Dec 31, 2025 | -43,000.00 |
| Dec 31, 2025 | -43,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Sep 30, 2025 | 200,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Jun 30, 2025 | 59,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Mar 31, 2025 | 93,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Dec 31, 2024 | -34,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Sep 30, 2024 | 132,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Jun 30, 2024 | 218,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Mar 31, 2024 | 266,000.00 |
| Dec 31, 2023 | 181,000.00 |
| Dec 31, 2023 | 181,000.00 |